Macquarie Group Ltd. Acquires 8,700 Shares of Horizon Pharma PLC (HZNP)

Macquarie Group Ltd. increased its holdings in Horizon Pharma PLC (NASDAQ:HZNP) by 207.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,900 shares of the biopharmaceutical company’s stock after acquiring an additional 8,700 shares during the quarter. Macquarie Group Ltd.’s holdings in Horizon Pharma were worth $188,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the company. Fox Run Management L.L.C. increased its holdings in shares of Horizon Pharma by 21.5% in the 4th quarter. Fox Run Management L.L.C. now owns 19,200 shares of the biopharmaceutical company’s stock valued at $280,000 after acquiring an additional 3,400 shares during the period. California Public Employees Retirement System grew its position in Horizon Pharma by 1.5% in the 4th quarter. California Public Employees Retirement System now owns 330,018 shares of the biopharmaceutical company’s stock valued at $4,818,000 after buying an additional 4,933 shares during the last quarter. New York State Common Retirement Fund grew its position in Horizon Pharma by 3.0% in the 3rd quarter. New York State Common Retirement Fund now owns 238,613 shares of the biopharmaceutical company’s stock valued at $3,026,000 after buying an additional 7,000 shares during the last quarter. Legal & General Group Plc grew its position in Horizon Pharma by 12.9% in the 3rd quarter. Legal & General Group Plc now owns 63,843 shares of the biopharmaceutical company’s stock valued at $809,000 after buying an additional 7,291 shares during the last quarter. Finally, Swiss National Bank grew its position in Horizon Pharma by 2.9% in the 4th quarter. Swiss National Bank now owns 278,156 shares of the biopharmaceutical company’s stock valued at $4,061,000 after buying an additional 7,800 shares during the last quarter. 86.55% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

A number of research firms recently weighed in on HZNP. Cantor Fitzgerald set a $17.00 price objective on shares of Horizon Pharma and gave the company a “buy” rating in a research report on Sunday. BidaskClub upgraded shares of Horizon Pharma from a “sell” rating to a “hold” rating in a research report on Wednesday, March 28th. Piper Jaffray reiterated a “buy” rating and issued a $22.00 price objective on shares of Horizon Pharma in a research report on Thursday, March 1st. Cowen reiterated a “buy” rating and issued a $24.00 price objective on shares of Horizon Pharma in a research report on Thursday, March 1st. Finally, ValuEngine lowered shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. Horizon Pharma presently has an average rating of “Buy” and a consensus price target of $18.64.

Shares of NASDAQ HZNP opened at $13.27 on Tuesday. The firm has a market cap of $2,260.17, a price-to-earnings ratio of 11.25, a P/E/G ratio of 0.58 and a beta of 1.24. Horizon Pharma PLC has a one year low of $9.45 and a one year high of $16.02. The company has a debt-to-equity ratio of 1.91, a quick ratio of 1.54 and a current ratio of 1.63.

Horizon Pharma (NASDAQ:HZNP) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.22 by $0.07. The company had revenue of $274.22 million for the quarter, compared to analyst estimates of $264.48 million. Horizon Pharma had a negative net margin of 38.87% and a positive return on equity of 18.44%. The business’s revenue was down 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 EPS. analysts forecast that Horizon Pharma PLC will post 1.43 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Macquarie Group Ltd. Acquires 8,700 Shares of Horizon Pharma PLC (HZNP)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/17/macquarie-group-ltd-acquires-8700-shares-of-horizon-pharma-plc-hznp.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply